Summit Therapeutics Announces Completion Of Enrollment In Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC; FDA Grants Fast Track Designation For Ivonescimab In 2L+ EGFRm NSCLC
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics has completed enrollment in its Phase III HARMONi trial for ivonescimab in EGFR-mutated NSCLC. The FDA has granted Fast Track designation for ivonescimab, with topline data expected in mid-2025.
October 03, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Summit Therapeutics has completed enrollment in its Phase III HARMONi trial for ivonescimab in EGFR-mutated NSCLC. The FDA has granted Fast Track designation, potentially accelerating the drug's development and review process.
The completion of enrollment in a Phase III trial is a significant milestone for Summit Therapeutics, indicating progress in their clinical development. The FDA's Fast Track designation suggests a potential for expedited review, which is positive for the company's prospects. These developments are likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100